PwPepwise

Efpeglenatide

Weight Loss

Long-acting GLP-1 agonist

Efpeglenatide is a once-weekly injectable medication belonging to the GLP-1 receptor agonist (GLP-1 RA) class — a family of drugs.

§Dosing at a glance

4 protocols · from the research
What it's forDoseHow oftenHowFor how long
Type 2 Diabetes — blood-sugar control (Once-Weekly)2 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.56 wks
Type 2 Diabetes — heart-related and Renal Outcomes4 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.—
Once-Monthly Dosing (Exploratory)8 mgWeeklySubcutaneousInjected just under the skin, into the fat layer.—
Weight Management in Non-Diabetic Adults4 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.20 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

Efpeglenatide is a once-weekly injectable medication belonging to the GLP-1 receptor agonist (GLP-1 RA) class — a family of drugs that mimic a natural gut hormone called glucagon-like peptide-1 to help regulate blood sugar, appetite, and body weight. Unlike most other GLP-1 RAs, efpeglenatide is based on exendin-4, a compound originally found in Gila monster venom, rather than on human GLP-1 itself. It is engineered with a long-acting antibody fragment that allows once-weekly dosing by subcutaneous injection.

In people with type 2 diabetes, efpeglenatide reduces HbA1c (a measure of long-term blood sugar control) across all tested doses2, and at higher doses also produces meaningful reductions in body weight and fasting blood glucose2,11. Most notably, in a large cardiovascular outcomes trial, efpeglenatide reduced the risk of serious heart events by 27% and kidney disease progression by 32% compared to placebo1. These cardio-renal benefits were observed regardless of whether patients were also taking a complementary drug class called SGLT2 inhibitors6. In people without diabetes, efpeglenatide produces clinically meaningful weight loss of approximately 6–7 kg over 20 weeks9. The most common side effects are gastrointestinal — nausea, vomiting, diarrhea — consistent with the broader GLP-1 RA drug class1,2,9.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Efpeglenatide is a long-acting exendin-4-based glucagon-like peptide-1 receptor agonist (GLP-1 RA) engineered for extended pharmacokinetic duration. It consists of the exendin-4 peptide sequence — a 39-amino acid peptide originally isolated from the salivary secretions of the Gila monster (Heloderma suspectum) — conjugated via a flexible linker to the Fc fragment of human immunoglobulin G4 (IgG4). This Fc fusion strategy confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic cleavage, reduces renal clearance, and exploits FcRn-mediated recycling to achieve a plasma half-life of approximately 135–180 hours (~6–7.5 days), directly supporting once-weekly subcutaneous dosing13. Peak plasma concentrations are reached 48–144 hours post-injection, and weekly dosing achieves low peak-to-trough ratios of 1.3–1.4, ensuring pharmacodynamically stable receptor occupancy throughout the dosing interval13.

Efpeglenatide acts as a full agonist at the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed on pancreatic beta cells, cardiac myocytes, renal tubular cells, enteroendocrine cells, and neurons of the central and peripheral nervous systems. GLP-1R activation stimulates adenylate cyclase, elevating intracellular cyclic AMP (cAMP), which potentiates glucose-stimulated insulin secretion and suppresses glucagon release in a glucose-dependent manner — explaining the low intrinsic hypoglycemia risk of the drug class2,11. Downstream effects include slowed gastric emptying (contributing to postprandial glucose flattening and the gastrointestinal adverse event profile), hypothalamic appetite suppression (driving weight reduction), and direct cardioprotective and renoprotective signaling through GLP-1R expressed in cardiovascular and renal tissues1,3.

The cardiovascular and renal benefits of efpeglenatide — a 27% reduction in MACE and 32% reduction in composite renal outcomes — follow a clear dose-response gradient, with the 6 mg dose producing statistically superior reductions compared to 4 mg for cardiovascular endpoints, while both doses retain significant kidney protection1,3. Importantly, mediation analyses demonstrate that efpeglenatide's 1.46% HbA1c reduction is overwhelmingly attributable to direct incretin-mediated insulin secretion rather than downstream non-glycemic changes; weight loss accounts for less than 3% of this glycemic benefit, and all measured non-glycemic factors combined account for less than 12%20. This differentiates efpeglenatide mechanistically from higher-weight-loss agents where indirect metabolic effects contribute more substantially to glucose lowering.

Pharmacokinetics are dose-proportional across the therapeutic range, supporting predictable and consistent pharmacodynamic responses13. Structurally, exendin-4 shares approximately 53% amino acid sequence homology with human GLP-1 but is resistant to DPP-4 cleavage at its N-terminus due to a glycine-to-glutamate substitution at position 2, distinguishing it from native GLP-1 analogues such as liraglutide and semaglutide. Importantly, no neutralizing antibodies against efpeglenatide were detected in clinical studies, a favorable immunogenicity profile that is attributable partly to the IgG4 Fc fusion tolerizing the immune system and partly to the non-human exendin scaffold11. The cardio-renal protective effects of efpeglenatide are preserved irrespective of concomitant SGLT2 inhibitor use, with point estimates suggesting potential additive renal benefit (renal composite HR 0.52 with combination)6, consistent with complementary rather than overlapping mechanisms of organ protection.

§04Evidence & efficacy

Evidence base
99Studies
37Human
0Animal

Efpeglenatide demonstrates robust, replicated efficacy across multiple therapeutic domains in type 2 diabetes.

Glycemic Control: All three tested doses (2, 4, and 6 mg once weekly) significantly reduce HbA1c compared to placebo in type 2 diabetes, with reductions of 0.5%, 0.8%, and 1.0% respectively from a baseline of approximately 8.1%2. A dose-response relationship is evident, with the 4 mg and 6 mg doses also producing significant reductions in body weight and fasting plasma glucose2,4,5. The 4 mg once-weekly dose is non-inferior to daily liraglutide 1.8 mg for HbA1c reduction11, and efpeglenatide 4 mg and 6 mg are non-inferior to dulaglutide 1.5 mg once weekly in head-to-head comparison17. Across all active doses, 61–72% of patients achieved HbA1c <7% versus 24% on placebo11.

Cardiovascular Outcomes: Efpeglenatide reduces the risk of major adverse cardiovascular events (MACE) by 27% compared to placebo (HR 0.73; 95% CI 0.58–0.92; P=0.007 for superiority) in high-risk type 2 diabetes patients1. The 6 mg dose specifically reduces MACE by 35% (HR 0.65; P=0.0027), while the 4 mg dose shows a consistent directional benefit3. These cardiovascular benefits are preserved regardless of concomitant SGLT2 inhibitor use6.

Renal Outcomes: Efpeglenatide reduces a composite renal outcome by 32% versus placebo (HR 0.68; 95% CI 0.57–0.79; P<0.001)1. The 6 mg dose achieves a 37% reduction in the kidney composite (HR 0.63; P<0.0001)3. Kidney benefits are consistent irrespective of SGLT2 inhibitor co-use and across the spectrum of baseline liver fibrosis severity6,14.

Weight Management: In non-diabetic adults with obesity, efpeglenatide produces placebo-adjusted weight reductions of 6.3–7.2 kg over 20 weeks across active dose arms, with significantly greater proportions achieving ≥5% and ≥10% weight loss thresholds9. In a meta-analysis of RCTs, efpeglenatide reduces body weight by a pooled mean of 1.15 kg versus control across all studied populations18.

Comparative Efficacy Context: In network meta-analysis, efpeglenatide ranks among the top GLP-1 RAs for all-cause mortality, cardiovascular mortality, MACE, and serious adverse event reduction alongside semaglutide and liraglutide10. Efpeglenatide's HbA1c-lowering effect is primarily mediated through its direct incretin mechanism, with weight loss accounting for less than 3% of the glycemic benefit20.

§05Safety

Efpeglenatide's safety profile is consistent with the GLP-1 receptor agonist drug class. Gastrointestinal adverse events — including nausea, vomiting, diarrhea, constipation, and bloating — are the most commonly reported side effects across all clinical trials and doses1,2,9,11. These effects are generally transient and mild to moderate in severity, with nausea and vomiting typically subsiding within approximately two weeks of initiation11. At higher doses and with the once-monthly regimen, peak-to-trough plasma concentration fluctuations are associated with oscillating gastrointestinal tolerability concerns12.

Hypoglycemia risk is low with efpeglenatide monotherapy, as expected for a GLP-1 RA used without concomitant insulin or sulfonylureas2,4,5. When used alongside basal insulin, hypoglycemia rates are higher — up to approximately 10% for level 2 events — reflecting the pharmacodynamic interaction rather than an intrinsic drug effect17. No neutralizing antibodies against efpeglenatide were detected in dose-ranging studies, a favorable immunogenicity finding11.

At the class level, GLP-1 RAs as a group increase the incidence of gallbladder disorders (+32%) and pancreatitis (+17%) compared to placebo; efpeglenatide specifically ranked among the lower-risk agents for pancreatitis in a network meta-analysis10. Efpeglenatide significantly increases heart rate, serum amylase, and serum lipase levels, consistent with known GLP-1 RA class pharmacology20. Discontinuation due to adverse events ranged from 5% to 19% across active dose arms in the weight management phase 2 study, reflecting dose-dependent tolerability9. In the AMPLITUDE-O cardiovascular outcomes trial, the adverse event profile did not differ meaningfully between patients on or off concomitant SGLT2 inhibitors, supporting the safety of combination use6.

§06History

Efpeglenatide emerged from the broader discovery of exendin-4, a 39-amino acid peptide isolated in 1992 from the venom gland of the Gila monster (Heloderma suspectum) by John Eng at the Veterans Affairs Medical Center in New York. Exendin-4 was recognized as a potent, DPP-4-resistant GLP-1 receptor agonist and became the molecular scaffold for exenatide, the first GLP-1 RA approved for clinical use (2005). Efpeglenatide was developed by Hanmi Pharmaceutical (South Korea) as a next-generation, long-acting derivative using Hanmi's proprietary LAPSCOVERY platform, which fuses the exendin-4 peptide to an IgG4 Fc fragment via a non-peptidic polyethylene glycol linker, extending the half-life to approximately 6–7.5 days13.

Sanofi licensed efpeglenatide from Hanmi in 2015, initiating a global phase 2 and phase 3 development program. Phase 2 dose-ranging studies established the pharmacokinetic profile and optimal dosing frequency13, and a phase 2 obesity study demonstrated significant weight loss in non-diabetic adults9. Phase 3 development included the AMPLITUDE program, comprising monotherapy (AMPLITUDE-M)2, active-comparator (AMPLITUDE-D versus dulaglutide), add-on to basal insulin (AMPLITUDE-L), and add-on to oral agents (AMPLITUDE-S) trials17, as well as the landmark AMPLITUDE-O cardiovascular outcomes trial, which enrolled over 4,000 high-cardiovascular-risk type 2 diabetes patients between 2018 and 201916. AMPLITUDE-O demonstrated significant cardiovascular and renal superiority over placebo, published in the New England Journal of Medicine in 20211 — the pivotal landmark study establishing efpeglenatide's cardiorenal profile. Despite this evidence base, Sanofi discontinued the efpeglenatide development program in 2021, and it has not received regulatory approval; Hanmi has continued to explore its clinical applications.

§07References